Plain-English translation of NCT04977453 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called (or an improved version called ) designed to help your immune system fight cancer. Researchers want to find the right dose and understand how safe and effective the treatment is, both when given alone and when combined with other existing cancer medications like pembrolizumab or .
Current cancer treatments don't work for everyone, and doctors need new options to help patients with advanced tumors. This medication works differently than traditional chemotherapy by activating your immune system to recognize and attack cancer cells, offering hope for better treatment outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive the medication through injections or infusions at clinic visits, starting at a low dose that may be increased over time as researchers learn how your body tolerates the treatment. Depending on which part of the study you join, you might receive the medication alone or combined with another cancer drug. You'll have regular blood tests, scans, and check-ins with your doctor to monitor how you're responding and watch for any side effects, with the study lasting several months or longer.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States
South Korea